ProsTIC key research

We can use radiolabelled prostate specific membrane antigen (PSMA) for PET (Positron Emission Tomography) imaging and treatment of patients with prostate cancer. We performed our first PSMA PET with Gallium-68 in 2014 and PSMA therapy with Lutetium-177 in 2015. Since 2017, we have also performed PSMA PET with Fluorine-18. Our multidisciplinary team has been actively involved in advancing research with over 55 publications related to PSMA imaging or therapy over the last five years

Our key publications